Loading...

Financial Statements

Apricus Biosciences Inc.

Apricus Biosciences Inc. (APRI)

Healthcare

Balance Sheet Statement

Download APRI income statement Download APRI income statement
Year 200920102011201220132014201520162017
Cash and cash equivalents 0.489.757.4915.1821.7411.694.172.096.33
Short-term investments ---------
Cash and short-term investments 0.489.757.4915.1821.7411.694.172.096.33
Receivables 1.350.540.020.650.060.680.52--
Inventories -0.00--0.340.280.47--
Property, Plant & Equipment Net 5.625.424.384.250.951.361.290.160.08
Goodwill and Intangible Assets 13.232.70-------
Long-term investments ---0.34-----
Tax assets ---------
Total non-current assets 4.054.981.786.490.585.982.040.920.75
Total current assets 19.178.398.422.981.051.521.561.070.11
Total assets 20.9318.8616.6223.8823.3114.817.784.706.71
Payables 1.550.231.052.280.930.861.580.760.06
Short-term debt 12.150.434.00-2.600.159.406.65-
Total current liabilities 14.172.3210.0210.7711.766.9115.6811.291.58
Long-term debt 3.104.10-3.41-4.63---
Total debt 15.264.534.003.412.604.789.406.65-
Deferred revenue 0.200.280.410.541.801.230.14-0.01
Tax Liabilities ---------
Deposit Liabilities ---------
Total non-current liabilities 4.054.981.786.490.585.982.040.920.75
Total liabilities 18.237.3011.8017.2612.3412.8917.7312.222.33
Other comprehensive income ---0.64-----
Retained earnings (deficit) -171.73-201.24-219.36-251.13-268.07-289.85-308.88-316.31-315.99
Total shareholders equity 2.7111.574.826.6210.971.92-9.94-7.524.37
Investments ---0.34-----
Net Debt 14.78-5.22-3.49-11.77-19.14-6.915.234.56-6.33
Other Assets -0.060.190.685.060.130.651.061.550.26
Other Liabilities 0.471.654.978.498.235.894.703.881.52

Apricus Biosciences Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Apricus Biosciences Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.